Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LYEL 
Lyell Immunopharma Inc (LYEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LYEL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.3% | Avg. Invested days 28 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 213.24M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 4 | Beta -0.2 | 52 Weeks Range 7.65 - 32.00 | Updated Date 08/29/2025 |
52 Weeks Range 7.65 - 32.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -24.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.1633 | Actual -2.89 |
Profitability
Profit Margin - | Operating Margin (TTM) -541212.5% |
Management Effectiveness
Return on Assets (TTM) -25.39% | Return on Equity (TTM) -76.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -16948658 | Price to Sales(TTM) 3554.07 |
Enterprise Value -16948658 | Price to Sales(TTM) 3554.07 | ||
Enterprise Value to Revenue 1938.09 | Enterprise Value to EBITDA 0.25 | Shares Outstanding 19211200 | Shares Floating 12047345 |
Shares Outstanding 19211200 | Shares Floating 12047345 | ||
Percent Insiders 20.56 | Percent Institutions 50.01 |
Upturn AI SWOT
Lyell Immunopharma Inc
Company Overview
History and Background
Lyell Immunopharma Inc. was founded in 2018. It focuses on developing T-cell reprogramming technologies to address solid tumors. The company has progressed from initial research to clinical trials.
Core Business Areas
- T-cell Reprogramming: Developing technologies to reprogram T-cells to overcome immunosuppression and other challenges in solid tumors.
Leadership and Structure
Liz Homans is the Chief Executive Officer. The company has a structured leadership team encompassing research, development, and operations.
Top Products and Market Share
Key Offerings
- Lyl-cel (ex vivo reprogrammed T cells): Lyl-cel is Lyellu2019s lead T-cell product candidate, engineered to address tumor escape. Currently in clinical trials, no market share or revenue. Competitors include companies with cell therapy products and pipelines like Gilead (Kite Pharma) (GILD) and Bristol Myers Squibb (BMY).
Market Dynamics
Industry Overview
The cell therapy industry is rapidly evolving, with increasing focus on solid tumors, which are harder to treat than hematological cancers. Advances in T-cell engineering and combination therapies are key drivers.
Positioning
Lyell is positioned as a leader in T-cell reprogramming for solid tumors, focusing on overcoming immunosuppression and T-cell exhaustion. Its competitive advantage lies in its proprietary technologies.
Total Addressable Market (TAM)
The TAM for solid tumor cell therapies is projected to be substantial, potentially reaching billions of dollars annually. Lyell is positioning itself to capture a significant share through its innovative approach.
Upturn SWOT Analysis
Strengths
- Proprietary T-cell reprogramming technologies
- Experienced management team
- Focus on a high unmet need (solid tumors)
- Strong partnerships and collaborations
Weaknesses
- Early stage clinical development
- High cash burn rate
- Reliance on clinical trial success
- Competition from larger pharmaceutical companies
Opportunities
- Positive clinical trial data
- Expansion of pipeline to new targets
- Strategic collaborations and partnerships
- Breakthrough Therapy Designation
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other cell therapy companies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- GILD
- BMY
- CRSP
- EDIT
Competitive Landscape
Lyell competes with established pharmaceutical companies in the cell therapy space. Its advantages lie in its novel reprogramming technologies. Disadvantages stem from being a smaller company with less established commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Lyell's historical growth is defined by preclinical and early clinical development. There is no meaningful historical revenue growth to analyze.
Future Projections: Future growth depends heavily on clinical trial outcomes and regulatory approvals. Analyst projections are varied and depend on pipeline success.
Recent Initiatives: Advancing lead candidate Lyl-cel through clinical trials, expanding pipeline, and fostering collaborations.
Summary
Lyell Immunopharma Inc. is a clinical-stage biotech company with promising T-cell reprogramming technologies. Its strength lies in its innovative approach to solid tumors. However, its success hinges on clinical trial outcomes and overcoming challenges of a high cash burn rate, making it a risky yet potentially high-reward investment. The company needs to carefully manage its cash runway and effectively navigate regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lyell Immunopharma Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary based on source. Information is based on publicly available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lyell Immunopharma Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-06-17 | President, CEO & Director Dr. Lynn Seely M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 300 | Website https://www.lyell.com |
Full time employees 300 | Website https://www.lyell.com | ||
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.